AI-guided AF Treatment

Artificial Intelligent Guided Treatment of Atrial Fibrillation: A Randomized Controlled Pilot Study

Two-centre, prospective, randomized, open-label, controlled pilot study to examine whether integrating an artificial intelligence virtual assistant (VA), instructed with the latest international guidelines on optimal patient management into the outpatient management of patients diagnosed with atrial fibrillation (AF) in the last 6 months, is feasible, acceptable and effective in reducing the need for regular medical assessment and the healthcare burden, reduce variability, and meets with participant satisfaction, without compromising participant safety and overall care quality.

Inclusion Criteria:

1. Age ≥ 18 years
2. Documented diagnosis of AF within the last 6 months
3. Patient is at least mildly symptomatic. Presence of at least one of the symptoms like palpitation, dizziness, breathlessness, pre-syncope, and syncope with at least mild intensity
4. Ability to understand and comprehend the study rationale, design, and process.

Exclusion Criteria:

1. Severe comorbidities (such as physical impairment, cognitive impairment, and hearing loss) that could affect protocol adherence, in the opinion of the investigator
2. Chronic Kidney Disease (CKD) stage 4-5 or on dialysis
3. Medical illness with a life expectancy of less than 1 year
4. Alternative potentially reversible causes of AF (such as surgery, sepsis, or thyroid dysfunction)
5. Dementia or other cognitive impairment
6. Currently involved in another AF interventional clinical trial
7. Being pregnant